Abbott Laboratories reported on Wednesday that its revenue for the first quarter of 2025 rose by 4% compared to the same period last year, reaching $10.4 billion. Net earnings came to $1.3 billion, growing 8.2% year-on-year, with diluted earnings per share (EPS) up 8.6% to $0.76.
"Once again, Abbott's diversified business model delivered top-tier sales and EPS growth. It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth," CEO Robert Ford said. The company reaffirmed its 2025 guidance, including organic sales growth of 7.5% to 8.5%, adjusted operating margin between 23.5% and 24.0% of sales, and adjusted diluted EPS between $5.05 and $5.25.
